IRD insider trading
HealthcareOpus Genetics, Inc.: insider trade history from SEC Form 4 filings.
About Opus Genetics, Inc.
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances; and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Durham, North Carolina.
Company website: opusgtx.com
IRD insider activity at a glance
FilingIQ tracks 81 insider transactions for IRD in filings since Oct 24, 2024. The most recent transaction is dated Sep 30, 2026.
Across the full history, 6 open-market purchases
and 18 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on IRD insider trades is 61.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest IRD Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading IRD
Frequently asked
- How many insider trades does FilingIQ track for IRD?
- FilingIQ tracks 81 Form 4 insider transactions for IRD (Opus Genetics, Inc.), covering filings from Oct 24, 2024 onwards. 9 of those are dated within the last 90 days.
- Are IRD insiders net buyers or net sellers?
- Across the full Form 4 history for IRD, 6 transactions (7%) were open-market purchases and 18 (22%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does IRD insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is IRD in?
- Opus Genetics, Inc. (IRD) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $251.03M.
Methodology & sources
Every IRD insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.